CYP2C19, cytochrome P450 family 2 subfamily C member 19, 1557
N. diseases: 274; N. variants: 14
Source: ALL
| Disease | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year |
|---|---|---|---|---|---|---|---|
|
|
0.100 | GeneticVariation | disease | BEFREE | Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. | 21361732 | 2011 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy. | 30403784 | 2019 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Twenty-five white patients were genotyped for CYP2C19 by allele-specific polymerase chain reaction amplification, and their Helicobacter pylori status was assessed by serology and with immunoblot analysis. | 10982760 | 2000 |
|
|
0.100 | GeneticVariation | disease | BEFREE | The present study aimed to assess the effects of CYP2C19 gene polymorphisms on proton pump inhibitor (PPI), amoxicillin, and levofloxacin triple therapy for Helicobacter pylori (Hp) eradication. | 28577017 | 2017 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Simultaneous detection of human CYP2C19 polymorphisms and antibiotic resistance of Helicobacter pylori using a personalised diagnosis kit. | 29444465 | 2018 |
|
|
0.100 | GeneticVariation | disease | BEFREE | In this study, we examined the usefulness of the prediction of the pharmacotherapeutic efficacy using a newly developed analysis system for HP CAM resistance and CYP2C19 genotypes. | 21132257 | 2011 |
|
|
0.100 | GeneticVariation | disease | BEFREE | But no study correlated CYP2C19 genetic polymorphism with eradication of Helicobacter pylori in north Indian gastritis patients positive for H. pylori and hence this study. | 19942749 | 2009 |
|
|
0.100 | GeneticVariation | disease | BEFREE | CYP2C19*2, *3, *4, *5 and *17 genotypes were determined in healthy Helicobacter pylori-negative Caucasian subjects. | 19785625 | 2010 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Methods : We determined CYP2C19 genotypes (CYP2C19*1, *2 and *3) in 111 Helicobacter pylori-positive patients with gastric cancer and 315 H. pylori-positive controls without gastric cancer consisting of patients with gastritis only or peptic ulcer. | 16268979 | 2005 |
|
|
0.100 | GeneticVariation | disease | BEFREE | We investigated whether the CYP2C19 genotype plays a role in the eradication rate of Helicobacter pylori (H. pylori) infection in patients receiving pantoprazole- or esomeprazole-based triple therapy. | 18637061 | 2008 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. | 24599773 | 2014 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. | 19552744 | 2009 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Our aim was to investigate prophylaxis effects of famotidine, one of the representative histamine-2 receptor antagonists (H2RA), on gastric mucosal injury induced by dual therapy with low-dose aspirin and clopidogrel in relation to Helicobacter pylori (H. pylori) infection and CYP2C19 genotypes. | 24615745 | 2014 |
|
|
0.100 | GeneticVariation | disease | BEFREE | To investigate whether MDR1 polymorphism is associated with eradication rates of Helicobacter pylori by a triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP2C19 genotype status and bacterial susceptibility to clarithromycin. | 17697203 | 2007 |
|
|
0.100 | GeneticVariation | disease | BEFREE | It has been suggested that proton pump inhibitor (PPI)-related differences in Helicobacter pylori eradication rates are partly because of CYP2C19 polymorphisms and there have been conflicting data in this area. | 16863547 | 2006 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study. | 27221874 | 2016 |
|
|
0.100 | GeneticVariation | disease | BEFREE | To investigate the effect of different proton pump inhibitors, S-mephenytoin 4'-hydroxylase (CYP2C19) genotype and antibiotic susceptibility on the eradication rate of Helicobacter pylori. | 12534411 | 2003 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy. | 30859680 | 2019 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Both clarithromycin-resistant Helicobacter pylori and CYP2C19 polymorphisms may be passed down for generations and are known risk factors for the failure of H. pylori eradication therapy. | 31264254 | 2019 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Fifteen Helicobacter pylori-negative volunteers with different CYP2C19 genotypes were randomly administered aspirin 100 mg, aspirin plus famotidine 20 mg twice daily, or aspirin plus lansoprazole 15 mg once daily for 7 days each in a crossover fashion. | 20663999 | 2011 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer. | 20457439 | 2010 |
|
|
0.100 | GeneticVariation | disease | BEFREE | The potential contribution of CYP2C19 genetic polymorphisms and the presence of Helicobacter pylori were also assessed. | 17645482 | 2007 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. | 24914361 | 2014 |
|
|
0.100 | GeneticVariation | disease | BEFREE | CYP2C19 metabolizer genotype and Helicobacter pylori status were examined. | 23800161 | 2013 |
|
|
0.100 | GeneticVariation | disease | BEFREE | First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. | 26730167 | 2015 |